Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Ivuxolimab

Catalog #:   DHE43201 Specific References (5) DATASHEET
Host species: Human
Isotype: IgG2-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHE43201

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG2-kappa

Clonality

Monoclonal

Target

ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P43489

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

PF-04518600, CAS: 2225940-98-5

Clone ID

Ivuxolimab

Data Image
  • SDS-PAGE
    SDS PAGE for Ivuxolimab
  • Bioactivity
    Detects CD134/TNFRSF4/OX40 in indirect ELISAs.
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies., PMID:40139261

Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily., PMID:38168220

A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma., PMID:37851072

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors., PMID:36302562

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers., PMID:34615725

Datasheet

Document Download

Research Grade Ivuxolimab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Ivuxolimab [DHE43201]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only